At Vitti Labs, we have developed VL-PX10 and VL-P22—an innovative therapy utilizing umbilical cord mesenchymal stem cell exosomes, stem cells, and natural biomaterials. This first-of-its-kind combination targets lung scarring in long-haul COVID-19 patients. We are proud to support healing and recovery with advanced regenerative science.
Mesenchymal Stem Cells Therapy for Pulmonary Fibrosis
Advancing research into pulmonary fibrosis through innovative clinical trials, Vitti Long Haul explores mesenchymal stem cells therapy, which focuses on reducing lung inflammation, supporting tissue regeneration, and slowing disease progression. This science-driven approach investigates how stem cells and their bioactive factors may help repair damaged lung tissue and improve outcomes for patients with fibrotic lung conditions.
Write a comment ...